home / stock / cydy / cydy news

CYDY News and Press, CytoDyn Inc From 06/01/20

Stock Information
Company Name: CytoDyn Inc
Stock Symbol: CYDY
Market: OTC
Website: cytodyn.com
Menu
CYDY CYDY Quote CYDY Short CYDY News CYDY Articles CYDY Message Board
Get CYDY Alerts

News, Short Squeeze, Breakout and More Instantly...
CYDY - CytoDyn to Present at Wall Street Reporter's Livestream Event on June 2, 2020 at 12:30 pm ET / 9:30 am PT

VANCOUVER, Washington, June 01, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced...
CYDY - CytoDyn Files Request With FDA for Priority Review of BLA for First Approval

If granted, the FDA is expected to take action on the Company’s BLA within six months VANCOUVER, Washington, June 01, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlima...

CYDY - Pandemic Damage And The Vaccine Industry

Introduction Think about it: the world is having a health crisis and what do we do? We created the largest global collapse since 1929! And as noted in prior columns , we are now at a point where nobody wanted to go: we must continually ask: do we continue the global “lockdownȁ...

CYDY - CytoDyn to Hold Conference Call to Provide Updates on COVID-19 (Phase 2, 3 & eIND), Cancer (mTNBC, Phase 2 for 22 Solid Tumor Cancers), HIV (BLA, Monotherapy), NASH, GvHD and MS

VANCOUVER, Washington, May 22, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced ...
CYDY - CytoDyn and Mexican NIH team up to evaluate leronlimab for treatment of COVID-19

CytoDyn ( OTCQB:CYDY ) will be coordinating with the National Institutes of Health (NIH) of Mexico and providing leronlimab for a trial for the severe/critical COVID-19 population in Mexico with the potential to collaborate on further CytoDyn COVID-19 trials. More news on: CytoDyn Inc., ...

CYDY - CytoDyn and the Mexican National Institutes of Health Participate in a Collaborative Study of Leronlimab for the Treatment of Severe/Critical COVID-19 Population

  The study is anticipated to consist of approximately thirty patients with potential involvement of the NIH of Mexico in other CytoDyn trials VANCOUVER, Washington, May 19, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company...

CYDY - CytoDyn to Prepare a Phase 3 Protocol to Submit to the FDA for a Three-Arm Comparative and Combination Trial of Leronlimab and Remdesivir

Three arms of this trial will be leronlimab, remdesivir, and leronlimab + remdesivir VANCOUVER, Washington, May 18, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab...
CYDY - CytoDyn to offer laboratory testing for childhood inflammatory disease associated with COVID-19

CytoDyn ( OTCQB:CYDY ) is offering comprehensive cytokine profiling through its diagnostic partner, IncellDx, to help physicians understand the pathogenesis of Childhood Inflammatory Disease Related to COVID-19. More news on: CytoDyn Inc., Healthcare stocks news, Read more ...

CYDY - CytoDyn to Offer No-Cost Exploratory Laboratory Testing for Childhood Inflammatory Disease Associated with COVID-19

VANCOUVER, Washington, May 15, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, tod...

CYDY - CytoDyn Completed Submission of All Remaining Parts of Biologics License Application ("BLA") on May 11, 2020

CytoDyn Submits Requested Datasets to FDA for Biologics License Application VANCOUVER, Washington, May 13, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 14...
Previous 10 Next 10